investors

Why invest in Aspen?

We have a proud heritage dating back more than 160 years and we are committed to sustaining life and promoting healthcare through increasing access to our high quality, affordable medicines and products.

Aspen is the largest pharmaceutical company listed on the South African securities exchange,  JSE Limited, and is one of the top 20 companies listed on this exchange. Our market capitalisation at 30 June 2017 was R131 billion (approximately USD10 billion). The Group has 25 manufacturing facilities at 17 sites on six continents and more than 10 000 employees.

We are well positioned in both developing and developed markets and we are the largest pharmaceutical company in Africa, with an expanding presence in Latin America, Asia, Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics. We are also one of the leading pharmaceutical companies in Australia and we are establishing a presence in other developed markets such as the United States of America and Canada.

QUICK FACTS

Market capitalisation


R131 billion

US$11 billion

Ranking in generic producers globally


9th largest

Manufacturing facilities


25

Sites


17

Continents


6

Employees


+10 000

INVESTMENT PROPOSITION

Please click on a title below left for more information.
Strong market position

Strong market position

  • One of the largest pharmaceutical companies in the southern hemisphere
  • Substantial presence in major developing markets such as Latin America, Russia, Eastern Europe, sub-Saharan Africa and South East Asia
  • Accredited manufacturing facilities that are scalable to demand
  • Vertical integration advantages for the manufacture of certain of Aspen’s leading global brands
  • The leading pharmaceutical company in South Africa
  • One of the top five pharmaceutical companies in Australia
Diversified geographies and product offering
Proven track record
Leverages on local knowledge and expertise
Centralised Group activities facilitate synergies and mitigate pricing pressures
Positive growth drivers
Responsible corporate citizen
Other considerations